Complete report $6,500. DataPack (test volumes, sales forecasts, supplier shares) $5,500.
This new 300-page report from Venture Planning Group provides a comprehensive analysis of the European drug of abuse testing market, including emerging tests, technologies, instrumentation, sales forecasts, market shares, and strategic profiles of leading suppliers.
The report provides test volume and sales forecasts by country and market segment for the following assays: Amphetamines, Antidepressants, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine, LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP), Propoxphene.
During the next five years, the abused drug testing market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.
This is a unique study designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study explores future trends; and provides test volume and sales forecasts, by market segment and individual assay.
Contains 300 pages and 48 tables